ASX Announcement Starpharma secures majority ownership of Petalion Starpharma to lead development of the FAP-targeted DEP® program, with Medicxi remaining a strategic partner and substantial shareholder • Starpharma has increased its equity interest in Petalion Therapeutics from 22.5% to 66%,...